PCLO Variants are Nominally Associated with Early Onset Type 2 Diabetes and Insulin Resistance in Pima Indians

Lijun Ma, Robert L. Hanson, Lorem N. Que, Yan Guo, Sayuko Kobes, Clifton Bogardus, and Leslie J. Baier

Diabetes Molecular Genetics Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Phoenix, AZ 85004

Address Correspondence to:
Leslie J. Baier, PhD
Diabetes Molecular Genetics Section
Phoenix Epidemiology and Clinical Research Branch
National Institute of Diabetes, Digestive and Kidney Diseases
National Institutes of Health
445 N. Fifth Street, Suite 210
Phoenix, AZ 85004.
E-mail: lbaier@phx.niddk.nih.gov

Received 20 December 2008 and accepted 15 July 2008.

Additional information for this article can be found in an online appendix at

http://diabetes.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
ABSTRACT

Objective: A prior genome-wide association (GWA) study in Pima Indians identified variants within PCLO that were associated with early-onset type 2 diabetes. PCLO encodes a presynaptic cytomatrix protein which functions as a Ca\(^{2+}\) sensor that may be involved in insulin secretion and/or insulin action. Therefore, PCLO was analyzed as a candidate gene for type 2 diabetes.

Research Design and Methods: Sequencing of PCLO identified 4 non-synonymous variants and a 10 amino acid insertion. These variants, together with 100 additional variants identified by sequencing or chosen from databases, were genotyped for association analysis in the same 895 subjects analyzed in the prior GWA study (300 cases with diabetes onset at age <25 years, 334 non-diabetic controls age >45, and 261 discordant siblings of the cases or controls for within-family analyses), as well as 415 non-diabetic Pima Indians who had been metabolically phenotyped for predictors of diabetes. Selected variants were further genotyped in a population-based sample of 3501 Pima Indians.

Results: Four variants were modestly associated with early-onset type 2 diabetes in both general and within-family analyses (\(P=0.004-0.04\), recessive model), where the diabetes risk allele was also nominally associated with a lower insulin-mediated glucose disposal rate (\(P=0.009-0.14\), recessive model) in non-diabetic Pima Indians. However, their association with diabetes in the population-based sample was weaker (\(p=0.02-0.20\), recessive model).

Conclusions: Variation within PCLO may have a modest effect on early-onset type 2 diabetes, possibly as a result of reduced insulin action, but has minimal, if any, impact on population-based risk for type 2 diabetes.
The Pima Indians of Arizona have an extremely high prevalence of type 2 diabetes (1). Their diabetes is characterized by obesity, dysfunction of insulin secretion, insulin resistance (decreased insulin-mediated glucose disposal), and increased rate of endogenous glucose output (2). Studies have shown that type 2 diabetes, insulin action, acute insulin response to glucose, and obesity are highly heritable in this population (3-5). To identify genes that underlie the development of type 2 diabetes in Pima Indians, we recently completed a genome-wide association (GWA) study using the Affymetrix 100K SNP genotyping array (6). Two single nucleotide polymorphisms (SNPs), rs10487656 and rs10487657, that ranked among the top 1% for a general association with early onset type 2 diabetes (defined as age of onset <25 years) mapped within an intron of the PCLO gene.

PCLO is located on chromosome 7q21 and encodes for a presynaptic cytomatrix protein which functions as a Ca$^{2+}$ sensor that could potentially have a role in insulin secretion and/or insulin action (7-10); therefore, PCLO was analyzed as a positional and physiological candidate gene for type 2 diabetes.

**Research Design and Methods**

**Subjects.** All subjects are part of our ongoing longitudinal study of the etiology of type 2 diabetes among the Gila River Indian Community in Central Arizona (1). Diabetes status is determined by a 75-g orally administered glucose tolerance test where the results are interpreted according to the criteria of the World Health Organization (11). All studies were approved by the Institutional Review Board of the National Institutes of Diabetes and Digestive and Kidney Diseases. The case/control subjects analyzed for association with early onset type 2 diabetes consisted of 300 cases (onset age <25 years, 38% male, mean maximum BMI = 38.9 ± 8.4 kg/m$^2$) and 334 non-diabetic controls (age >45 years, 48% male, mean maximum BMI = 35.4 ± 8.0 kg/m$^2$). To control for potential population stratification, 261 additional subjects who were discordant siblings of the cases/controls were also genotyped to allow for within-family association analyses (total of 340 discordant sib pairs from 172 informative sibships). A larger population-based sample of 3501 full-heritage Pima Indians consisting of 1561 subjects with type 2 diabetes (age = 37.2 ± 12.1 years, 27% male, mean maximum BMI = 38.5 ± 8.4 kg/m$^2$) and 1940 subjects without type 2 diabetes (age = 31.1 ± 14.5 years, 46% male, mean maximum BMI = 35.7 ± 8.2 kg/m$^2$) was also analyzed.

For association analysis with traits that predict type 2 diabetes, 415 non-diabetic, full-heritage Pima Indians (57.9% male, age = 26.7 ± 6.2 years, BMI = 34.0 ± 7.5 kg/m$^2$) who had been metabolically studied as inpatients in our clinical research center were genotyped. These non-diabetic inpatients were determined to be healthy by medical history, physical examination, and routine laboratory tests, and were not taking medications. Oral glucose tolerance was measured after 2-3 days on a weight-maintaining diet of mixed composition. Blood for plasma glucose and insulin measurements was drawn before ingesting 75-g of glucose, and at 30, 60, 120, and 180 min thereafter. Subjects also received a 25-g intravenous injection of glucose over 3 min to measure the acute insulin response (AIR). Blood samples were collected before infusion and at 3, 4, 5, 6, 8, and 10 min after infusion for determination of plasma glucose and insulin concentrations. AIR was calculated as the mean increment in plasma insulin concentrations from 3 to 5 min (12). The hyperinsulinemic-euglycemic clamp technique was used to determine basal
glucose appearance and insulin-stimulated glucose disappearance (uptake) rates as described elsewhere (12).

**Single nucleotide polymorphism identification and genotyping.** To identify novel sequence variants, all 27 exons, exon-intron boundaries, 5’ and 3’-untranslated regions, and 2kb of the putative promoter region of PCLO were sequenced in DNA samples from 24 non-first-degree related Pima Indians (12 developed diabetes with an onset age <25 years, and 12 were non-diabetic and >45 years of age). Sequencing was performed using Big Dye Terminator technology (Applied Biosystems) on an automated DNA capillary sequencer (model 3730xl; Applied Biosystems). SNPs were genotyped by SNPlex (Applied Biosystems) following the manufacturer’s protocol.

**Expression and tissue distribution.** Primers designed for the major PCLO transcript (XM_929946; NCBI) were used to amplify cDNA from the human tissues: adipose, hypothalamus, pituitary (BD Marathon-Ready cDNA; BD Bioscience/Clontech), brain, skeletal muscle, heart, liver, kidney, spleen, pancreas (BD Human MTC Multiple Tissue cDNA Panels I and II; BD Bioscience/Clontech), and pancreatic islets (kindly provided by Dr. Lorella Marcelli at Joslin Diabetes Center). PCR products were sequenced to confirm that they encoded PCLO.

**Statistical Analysis.** Statistical analyses were performed using the version 8.0 software of the SAS (Cary, NC, USA). Numeric variables are expressed as mean±SE. For continuous variables, the general estimating equation (GEE) procedure was used to adjust for the appropriate covariates, and to account for the correlation among siblings. For insulin-stimulated glucose disposal rates (M) measured during the clamp the covariates were age, gender, % body fat and M. The glucose disposal rates during the clamp were log transformed prior to analyses to approximate a normal distribution.

In the case/control analysis for early onset type 2 diabetes, a logistic regression was used to adjust for gender, birth date, and sibship. For the population based analysis, a survival analysis (Poisson model) was used to analyze the association of genotype with development of diabetes with adjustment for gender and birth date; to account for sibship, this model was also fit with generalize estimating equations. To control for potential population stratification, the association with diabetes was also analyzed using a within-family association test (13). We estimate the power of the case/control sample is >75% to detect a common (minor allele frequency >0.1) functional allele at P <0.001 that explains 1.6% of the variance in age of onset of diabetes for the general test and 3% of the variance for the within-family test. Similarly we estimate the power of the population sample is 92% to detect an odds ratio of 1.2 at P <0.05 for a marker with allele frequency = 0.5. However, the magnitude of the associations between several recently reported SNPs and type 2 diabetes in Caucasians has been quite modest (odds ratios ~1.15) (14-19). We estimate that the power of our population-based sample to detect an odds ratio of 1.15 is ~79% for a risk allele with frequency of 0.5 and ~35 % for a risk allele with frequency of 0.1. The 95% confidence intervals for the odds ratios can provide a measure of the range of effect sizes consistent with the data.

Homozygotes for the risk allele (1/1), heterozygotes (1/2), and homozygotes for the protective allele (2/2) were coded to a continuous numeric variable for genotype as 2, 1, and 0 respectively. The recessive model was defined as contrasting genotypic groups 1/1 vs 1/2 + 2/2. To examine pair-wise linkage disequilibrium (LD), haplotype frequencies were estimated with the
Estimating Haplotype (EH) program of Xie and Ott (http://linkage.rockefeller.edu/ott/eh.htm), and these haplotype frequencies were used to calculate D’ and r².

**RESULTS AND DISCUSSION**

Sequencing of *PCLO* identified variation that predicted a 10 amino acid insertion at codon 375, and 4 amino acid substitutions at Ser4684Ala (rs2522833), Ala2742Thr (rs976714), Val2413Ile (rs10954696), and Asp287Gly (novel). These 5 variants, together with 100 additional SNPs identified by sequencing or selected from public databases to approximate a 5 kb dense coverage across the *PCLO* locus were genotyped for association analysis in the same 895 early-onset type 2 diabetes case/control subjects that were analyzed in our prior GWA study (all 105 variants are listed in online Table 1 and the linkage disequilibrium [LD] pattern between these variants is shown in online Fig. 1). All of the variants were in Hardy-Weinberg equilibrium. Four common SNPs (Ala2742Thr, Val2413Ile, and intronic SNPs rs10487656 and rs6950504) were associated with early-onset type 2 diabetes under both general and within-family analyses where both recessive $P<0.05$ (Table 1).

The 105 variants were additionally genotyped in 415 full heritage, non-diabetic subjects who had been metabolically phenotyped for predictors of type 2 diabetes including acute insulin response to an intravenous glucose bolus and insulin-stimulated glucose disposal rate during a hyperinsulinemic-euglycemic clamp. The 4 SNPs (Table 1) that were associated with early-onset type 2 diabetes under both general and within-family analyses where both recessive $P<0.05$ (Table 1).

To determine the significance of variation in *PCLO* on diabetes risk in the general Pima Indian population, the 4 SNPs were further genotyped in a population-based sample of 3501 full-heritage Pima Indians, as defined as, all subjects from our longitudinal study for whom there was DNA available and diabetic status was known (1561 subjects had a diagnosis of type 2 diabetes and 1940 were non-diabetic at their last exam). The association of these SNPs with type 2 diabetes (as defined as onset at any age) was weaker in the larger population-based sample (Table 1, Development of type 2 diabetes in a population-based sample). One explanation for observing a weaker association in the larger group of subjects is that *PCLO* may have a greater role in the development of early-onset type 2 diabetes as compared to diabetes at older ages (mean age of diabetes onset is 19.2 ± 4.5 years in the case/control sample and 37.2 ± 12.1 years in the population sample). Alternatively, the associations among the case/control subjects for early-onset type 2 diabetes and the associations with insulin action in the non-diabetic subjects may represent false positives. Indeed, the $P$ values given in this study are unadjusted for multiple comparisons, and, if corrected for the 105 variants studied (which could be argued to be an overcorrection due to high LD among many of the variants), none of the $P$ values would be significant. However, it remains controversial as to whether multiple comparison correction is appropriate for a potential physiologic candidate gene. In the present study, we instead chose to use both a case/control general and a within-family analysis to help restrict the number of false positive associations while retaining statistical power.

It is also noteworthy that the 500K GWA study performed at the Wellcome Trust Case
Control Consortium (WTCCC; www.wtccc.org.uk/info/summary_stats.shtml) also identified nominal associations between 8 SNPs (with allele frequencies >0.02) in \textit{PCLO} and type 2 diabetes (Table 2). Although these SNPs only showed a non-significant trend in another 500K GWA study of Scandinavians (DGI; www.broad.mit.edu/diabetes), they were significantly associated with type 2 diabetes in a meta-analysis of subjects of European descent (DIAGRAM) (20). Five of these 8 SNPs were also genotyped in the Pima Indian case/control sample and several had nominal associations with type 2 diabetes (Table 2). The best SNPs in Pima Indians (listed in Table 1) were not represented on the 500K chip; however, several of the WTCCC/DIAGRAM SNPs nominally associated with type 2 diabetes were in high LD with these SNPs in both Caucasians and Pima Indians (Figure 2). For example, rs7781142 and rs7799260 (Table 2), which are in complete LD (D' = 1; r^2 = 1) in both Caucasians (CEU) and Pima Indians, were in high LD with rs976714 (Ala2742Thr) and rs10954696 (Val2413Ile) in both Caucasians (D' = 1 and r^2 = 0.56) and Pima Indians (D' = 1 and r^2 = 0.53) (Figure 2).

\textit{PCLO} is known to be a Ca^{2+} sensor in pancreatic \( \beta \) cells (7) and the formation of a cAMP-GEFII·Rim2·Piccolo complex in \( \beta \) cells is important in insulin secretion (8). However, variants in this gene were not associated with the acute insulin response to a 25-g intravenous glucose bolus infusion or the 30 minute insulin response to a 75-g OGTT among normal glucose tolerant Pima Indians (data not shown). Based on our associations, we propose that \textit{PCLO} may also have a subtle role in the regulation of insulin sensitivity in insulin responsive tissues. As a first step to test this hypothesis, we have shown that \textit{PCLO} is ubiquitously expressed, with notable levels of expression in insulin responsive tissues such as adipose and liver (online Figure 2). Another example of a Ca^{2+} sensor having a role modulating insulin sensitivity is the \( \alpha_1 \)-subunit of the voltage-dependent calcium channel (VDCC), which has been previously associated with insulin resistance and type 2 diabetes in animal models (21) and humans (22). The Ca^{2+} sensor \textit{PCLO} could potentially interact with VDCC to influence insulin sensitivity.

In summary, we found a modest association of \textit{PCLO} variants with early onset type 2 diabetes, where the association was further supported by quantitative trait analysis in non-diabetic Pima Indians. However, this association was not well-substantiated in a population-based sample of Pima Indians. We conclude that \textit{PCLO} variants may modestly increase risk for early-onset type 2 diabetes, possibly as a result of altered insulin action, but variation in this gene does not appear to influence the population-based risk for developing diabetes among full-heritage Pima Indians.

\textbf{ACKNOWLEDGEMENTS}

We thank Drs. Michael Traurig and Yunhua L. Muller for their critical reading of this manuscript, and the staff of the Phoenix Epidemiology and Clinical Research Branch of NIDDK for their contributions to this study. We also thank the investigators from WTCCC, DGI and DIAGRAM for making their genotypic data publicly available; this is a tremendous resource that will benefit everyone in our goal to understand the genetics of complex diseases. This study was supported by the intramural research program of NIDDK, NIH. Drs. Ma and Guo are supported by a grant from the American Diabetes Association.
REFERENCES

1. Knowler WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 108:497-505, 1978

2. Bogardus C: Metabolic abnormalities in the development of non-insulin dependent diabetes mellitus. In Diabetes mellitus: A Fundamental and Clinical Text. D LeRoith, SI Taylor, JM Olefsky, Eds. Philadelphia, PA, Lippincott-Raven, p.459 –467, 1996

3. Baier LJ, Hanson RL: Genetic studies of the etiology of type 2 diabetes in Pima Indians: hunting for pieces to a complicated puzzle. Diabetes 53:1181–1186, 2004

4. Ravussin E, Bogardus C: Energy expenditure in the obese: is there a thrifty gene? Infusionstherapie 17:108–112, 1990

5. Sakul H, Pratley R, Cardon L, Ravussin E, Mott D, Bogardus C: Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians. Am J Hum Genet 60:651–656, 1997

6. Hanson RL, Bogardus C, Duggan D, Kobes S, Knowlton M, Infante AM, Marovich L, Benitez D, Baier LJ, Knowler WC: A search for variants associated with Young-onset type 2 diabetes in American Indians in a 100K genotyping array. Diabetes 56: 3045 -3052, 2007

7. Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, Tajima N, Iwanaga T, Seino S: Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2.Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 277:50497-50502, 2002

8. Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S: Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis. J Biol Chem 279:7956-7961, 2004

9. Shibasaki T, Sunaga Y, Seino S: Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis. Diabetes 53 Suppl 3:S59-62, 2004

10. Lanner JT, Katz A, Tavi P, Sandström ME, Zhang SJ, Wretman C, James S, Fauconnier J, Lännergren J, Bruton JD, Westerblad H: The role of Ca2+ influx for insulin-mediated glucose uptake in skeletal muscle. Diabetes 55:2077-2083, 2006

11. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)

12. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-92, 1993

13. Abecasis GR, Cardon LR, Cookson WO: A general test of association for quantitative traits in nuclear families. Am J Hum Genet 66:279-292, 2000
14. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445: 881-885, 2007

15. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatay A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gallet JR, Thorsteinsdottir U, Kong A, Stefansson K A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat. Genet. 39:770-775, 2007

16. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Boström K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Råstam L, Speliotes EK, Taskinen MR, Tuomilehto J, Amin R, Herberts P, Burger H, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjögren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabrielle GB, Chaim GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331-1336, 2007

17. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345, 2007

18. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS; Wellcome Trust Case Control Consortium (WTCCC), McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336-1341, 2007

19. The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common disease and 3,000 shared controls. Nature 447:661-678, 2007

20. Zeggini E, Scott LJ, Saxena R, Voight BF, for the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium: Meta-analysis of Genome-wide Association Data and...
Large-scale Replication Identifies Additional Susceptibility Loci for Type 2 Diabetes. Nature Genetics 40: 638-645, 2008

21. Matsuda Y, Saegusa H, Zong S, Noda T, Tanabe T: Mice lacking Ca(v)2.3 (alpha1E) calcium channel exhibit hyperglycemia. Biochem Biophys Res Commun 289:791-795, 2001

22. Li Muller Y, Hanson RL, Zimmerman C, Harper I, Sutherland J, Kobes S, The International Type 2 diabetes 1q Consortium, Knowler WC, Bogardus C, Baier LJ: Variants in the Cav2.3 (alpha1E) Subunit of Voltage-Activated Ca2+ Channels are Associated with Insulin Resistance and Type 2 diabetes in Pima Indians. Diabetes 56: 3089 -3094, 2007
Table 1. Association of 4 SNPs in *PCLO* with type 2 diabetes in a case/control sample and development of type 2 diabetes in a population-based sample of Pima Indians.

| SNP                  | Risk allele Frequency | Early-onset type 2 diabetes in a case/control sample | Development of type 2 diabetes in a population-based sample |
|----------------------|-----------------------|------------------------------------------------------|-------------------------------------------------------------|
|                      |                       | Adjusted* P value / Odds ratio (95% CI) | General | Within-family | Adjusted† P value / Hazard ratio (95% CI) | General | Within-family |
| Ala2742Thr (rs976714) (G/A) | 0.50 | 0.004 | 1.83(1.20-2.78) | 0.02 | 1.95(1.09-3.52) | 0.02 | 1.12(1.02-1.23) | 0.04 | 1.18(1.00-1.38) |
| Val2413Ile (rs10954696) (G/A) | 0.50 | 0.009 | 1.75(1.15-2.67) | 0.03 | 1.96(1.07-3.58) | 0.05 | 1.10(1.00-1.21) | 0.06 | 1.17(0.99-1.39) |
| rs10487656 (A/G) | 0.57 | 0.009 | 1.65(1.13-2.42) | 0.02 | 1.95(1.08-3.51) | 0.04 | 1.09(1.00-1.19) | 0.15 | 1.11(0.96-1.28) |
| rs6950504 (G/A) | 0.62 | 0.004 | 1.78(1.19-2.65) | 0.04 | 2.02(1.02-4.00) | 0.08 | 1.08(0.99-1.17) | 0.20 | 1.10(0.95-1.28) |

The case/control sample is composed of 895 Pima subjects, 300 cases with diabetes onset age <25 years, 334 non-diabetic controls age >45, and 261 additional sibs of either case or control group for within-family test. The population based sample consists of 3501 full heritage Pima Indians, 1561 diabetic and 1940 non-diabetic at the last visit. Most of the case/control subjects (N = 715) were included in the population-based sample. *In the case/control analysis, a logistic regression was used to adjust for gender, birth year, and family membership. †For the population based-sample, a survival analysis (Poisson model) was applied to adjust for gender, birth year, age of last visit, age of onset for diabetes, and family membership. All P are for a recessive genetic model.
Table 2. SNPs in *PCLO* associated with type 2 diabetes in the WTCCC 500K GWA and their corresponding associations in the DGI 500K GWA, the DIAGRAM meta-analysis, and Pima Indians

| SNP          | Alleles (1/2) | WTCCC | DGI | DIAGRAM | Pima Indians |
|--------------|---------------|-------|-----|---------|--------------|
|              |               | Case (f1) | Control (f1) | P<sub>add</sub> | Case (f1) | Control (f1) | P<sub>add</sub> | P<sub>add</sub> | Case (f1) | Control (f1) | P<sub>add</sub> | P<sub>add</sub> |
| rs34608268   | A/C           | 0.56   | 0.53 | 0.004   | 0.53   | 0.51   | 0.16 | — | — | — | — | — |
| rs2715148    | C/A           | 0.52   | 0.49 | 0.02    | 0.50   | 0.49   | 0.32 | 0.005 | 0.74 | 0.73 | 0.36 | 0.35 |
| rs2888019    | C/T           | 0.52   | 0.49 | 0.02    | 0.51   | 0.49   | 0.34 | 0.003 | 0.75 | 0.70 | 0.07 | 0.15 |
| rs1986742    | T/C           | 0.52   | 0.50 | 0.02    | 0.50   | 0.49   | 0.33 | 0.004 | — | — | — | — |
| rs9690648    | A/G           | 0.92   | 0.94 | 0.02    | 0.95   | 0.96   | 0.17 | 0.01 | 0.88 | 0.85 | 0.09 | 0.10 |
| rs7799260    | C/G           | 0.54   | 0.52 | 0.06    | 0.53   | 0.51   | 0.32 | 0.004 | 0.70 | 0.64 | 0.05 | 0.04 |
| rs7778238    | C/G           | 0.54   | 0.52 | 0.07    | 0.52   | 0.51   | 0.33 | 0.005 | 0.70 | 0.64 | 0.05 | 0.04 |
|              |               | 0.51   | 0.49 | 0.06    | 0.52   | 0.51   | 0.19 | 0.002 | — | — | — | — |

The frequency of allele 1 (f1) for each SNP is given for cases (subjects with type 2 diabetes) and controls in each individual population. Frequency information was not available for the DIAGRAM meta-analysis, which combined data from the WTCCC, DGI and FUSION studies of subjects from European descent (20). Data for WTCCC was obtained from http://www.wtccc.org.uk/info/summary_stats.shtml.

Data for DGI was obtained from http://www.broad.mit.edu/diabetes. P values are calculated by comparison of genotypes. P values for WTCCC, DGI and DIAGRAM are given for an additive model (P<sub>add</sub>). P values for the Pima Indians are given for both an additive (P<sub>add</sub>) and a recessive model (P<sub>rec</sub>).
Figure 1. Mean insulin sensitivity by genotype among non-diabetic Pima Indians

Insulin-stimulated glucose uptake (mg/kgEMBS•min) was measured by a hyperinsulinemic-euglycemic clamp with insulin infusion at physiologic concentrations. *P* values are given for a recessive model for both a general association (*) and a within family association (†), and are adjusted for age, gender, percentage of body fat, and family membership. EMBS: estimated metabolic body size
Figure 2. Linkage disequilibrium (LD) pattern between SNPs in Table 1 (*) and Table 2 (†) in Caucasians and Pima Indians.

LD in Caucasians was determined by CEU data (www.HapMap.org) using HaploView (www.broad.mit.edu/mpg/haploview). rs34608268 from Table 2 could not be included in this figure because there was no publicly available HapMap data for this SNP, and 2 SNPs (rs1986742 and rs7778238) were omitted from the LD pattern in Pima Indians because these SNPs were not genotyped in Pima Indians.